Drug Profile
CA 002
Alternative Names: CA-002; Peanut oral immunotherapy - CamallergyLatest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator Cambridge University Hospitals
- Class Antiallergics; Food allergy immunotherapies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Peanut hypersensitivity
Most Recent Events
- 29 Nov 2023 Camallergy enters into collaboration with OnDosis to revolutionize food allergy treatment
- 01 Jul 2022 The US FDA accepts IND application for CA 002 in Peanut hypersensitivity for planned phase III trials
- 01 Jul 2022 Camallergy plans a phase III trial for Peanut hypersensitivity (In Children, In adults) in USA and Europe